a, Model of AAC (not drawn to scale). b, Mechanism of AAC action. c, Binding of Alexa-488 anti-β-GlcNAC WTA monoclonal antibody (mAb) or anti-α-GlcNAC WTA monoclonal antibody, or isotype control antibody, anti-cytomegalovirus glycoprotein-D (gD) to USA300 isolated from infected kidneys (n = 3). MFI, mean fluorescence intensity. d, Binding of anti-GlcNAC WTA antibodies (red) or isotype control (grey) to protein-A-deficient USA300 lacking tarM or tarS (n = 3). WT, wild type. e, Crystal structure of anti-β-GlcNAc WTA Fab bound to a synthetic minimal β-WTA unit. Antibody light chain (pink) and heavy chain (blue) are shown. f, MIC determination for rifampicin and rifalogue on USA300 (n = 5). g, Survival of stationary phase USA300 incubated with 1 × 10−6 M rifampicin or rifalogue (n = 4). h, USA300 bacteria were incubated without antibiotic (black) or with 3 μg ml−1 ciprofloxacin (Cipro; green, red and grey). 1 μg ml−1 of rifalogue (red) or rifampicin (grey) was added as indicated (n = 3). i, Intact AAC does not kill planktonic bacteria but does after pre-treatment with cathepsin-B (n = 3). g–i, Error bars show s.d. for triplicate samples (n = biological repeats).
Enlace al trabajo
No hay comentarios:
Publicar un comentario
Nota: solo los miembros de este blog pueden publicar comentarios.